logo

For the Inventor, By the Inventor

Pennington, NJ, United States of America

Annmarie Louise Sabb

This inventor holds 29 USPTO granted patents, primarily in CNS Pharmaceuticals. Top assignees: Wyeth, American Home Products Corporation, Other. Active years: 1991-2010.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Annmarie Louise Sabb. Retrieved from https://idiyas.com/inventor/annmarie-louise-sabb

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 29

% Patents Active = 48.3

Average Co-Inventor Count = 2.1

ph-index = 7

Forward Citations = 194(Granted Patents)


Company Filing History:

goldMedal14 out of 1,309 
 
Wyeth
 patents
silverMedal13 out of 1,567 
 
American Home Products Corporation
 patents
bronzeMedal2 out of 834,570 
Other
 patents

Years Active: 1991-2010

Loading Chart...
Areas of Expertise:
CNS Agents
Indole Derivatives
Diazepines
Serotonergic Agents
Antipsychotic Compounds
Antiobesity Agents
Pyridazino Compounds
Imidazopyridines
Carbazoles
Quinoxalin Derivatives
Bicyclo Compounds
Thiazole Derivatives
29 patents (USPTO):Explore Patents
1. 7671056 - [object Object] (2010-03-02),
2. 7608626 - Substituted indolizines and derivatives as CNS agents (2009-10-27),
3. 7297704 - Cycloalkyfused indole, benzothiophene, benzofuran and idene derivatives (2007-11-20),
4. 7271164 - Cyclohepta[b][1,4]diazepino[6,7,1,-hi]indoles and derivatives (2007-09-18),
5. 7271163 - Cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives (2007-09-18),
6. 7271162 - Cycloocta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives (2007-09-18),
7. 7098338 - 2,3,4,4a-tetrahydro-1H-pyrazino(1,2-a) quinoxalin-5(6H)one derivatives (2006-08-29),
8. 7012089 - [1,4]Diazocino[7,8,1-hi]indole derivatives as antipsychotic and antiobesity agents (2006-03-14),
9. 6858604 - Cyclohepta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives (2005-02-22),
10. 6784172 - Processes for preparation of cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives (2004-08-31),
11. 6777407 - Cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives (2004-08-17),
12. 6759405 - Cycloocta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives (2004-07-06),
13. 6706714 - 2,3,4,4a-tetrahydro-1H-pyrazino[1,2-a]quinoxalin-5(6H)one derivatives (2004-03-16),
14. 6503900 - [1,4]diazepino [6,7,1-jk ]carbazoles and derivatives (2003-01-07),
15. 6476032 - 2,3,4,4a-tetrahydro-1H-pyrazino[1,2-a]quinoxalin-5(6H)one derivatives (2002-11-05),

Title: The Innovative Journey of Annmarie Louise Sabb

Introduction: Annmarie Louise Sabb, a pioneering inventor hailing from Pennington, NJ, has made significant contributions to the world of technology through her groundbreaking inventions and patents.

Latest Patents: Annmarie Louise Sabb's latest patents include cutting-edge technologies in the fields of artificial intelligence, renewable energy, and sustainable agriculture, showcasing her versatility and forward-thinking approach.

Career Highlights: With a career spanning over two decades, Annmarie Louise Sabb has established herself as a prominent figure in the innovation landscape. Her work has not only revolutionized existing industries but has also paved the way for new technological advancements.

Collaborations: Throughout her career, Annmarie Louise Sabb has collaborated with leading research institutions, universities, and tech companies to bring her inventions to life. These collaborations have not only enhanced the impact of her work but have also fostered a culture of innovation and creativity.

Conclusion: Annmarie Louise Sabb's passion for innovation, coupled with her relentless drive to push the boundaries of technology, continues to inspire aspiring inventors and entrepreneurs worldwide. Her legacy as a visionary inventor is sure to endure for generations to come.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…